{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:16:32Z","timestamp":1787926592526,"version":"build-2784847793"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12666-1","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:16:55Z","timestamp":1787923015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling the role of p53 in the pathogenesis and treatment of autoimmune rheumatic diseases"],"prefix":"10.1007","volume":"53","author":[{"given":"Fatemeh","family":"Akbarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Farhadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Vodjgani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmadreza","family":"Jamshidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"12666_CR1","doi-asserted-by":"publisher","unstructured":"Lane DP (Jul. 1992) p53, guardian of the genome. Nature 358(6381):15\u201316. https:\/\/doi.org\/10.1038\/358015a0","DOI":"10.1038\/358015a0"},{"key":"12666_CR2","doi-asserted-by":"publisher","unstructured":"Lane DP, Crawford LV (Mar. 1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278:261\u2013263. https:\/\/doi.org\/10.1038\/278261a0","DOI":"10.1038\/278261a0"},{"key":"12666_CR3","doi-asserted-by":"publisher","unstructured":"Toshiyuki M, Reed JC (Jan. 1995) Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80(2):293\u2013299. https:\/\/doi.org\/10.1016\/0092-8674(95)90412-3","DOI":"10.1016\/0092-8674(95)90412-3"},{"key":"12666_CR4","doi-asserted-by":"publisher","unstructured":"Seoane J, Le H-V, Massagu\u00e9 J (2002) Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage, Nature, vol. 419, no. 6908, pp. 729\u2013734, Oct. https:\/\/doi.org\/10.1038\/nature01119","DOI":"10.1038\/nature01119"},{"key":"12666_CR5","doi-asserted-by":"publisher","unstructured":"Liu Y, Gu W (Oct. 2022) The complexity of p53-mediated metabolic regulation in tumor suppression. Sem Cancer Biol 85:4\u201332. https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.010","DOI":"10.1016\/j.semcancer.2021.03.010"},{"key":"12666_CR6","doi-asserted-by":"publisher","unstructured":"Spike BT, Wahl GM (2011) p53, Stem Cells, and Reprogramming: Tumor Suppression beyond Guarding the Genome, Genes & Cancer, vol. 2, no. 4, pp. 404\u2013419, Apr. https:\/\/doi.org\/10.1177\/1947601911410224","DOI":"10.1177\/1947601911410224"},{"key":"12666_CR7","doi-asserted-by":"publisher","unstructured":"Boutelle AM, Attardi LD (Apr. 2021) p53 and Tumor Suppression: It Takes a Network. Trends Cell Biol 31(4):298\u2013310. https:\/\/doi.org\/10.1016\/j.tcb.2020.12.011","DOI":"10.1016\/j.tcb.2020.12.011"},{"key":"12666_CR8","doi-asserted-by":"publisher","unstructured":"Xu R, Wang W, Zhang W (2023) Ferroptosis and the bidirectional regulatory factor p53, Cell Death Discov., vol. 9, no. 1, p. 197, Jun. https:\/\/doi.org\/10.1038\/s41420-023-01517-8","DOI":"10.1038\/s41420-023-01517-8"},{"key":"12666_CR9","doi-asserted-by":"publisher","unstructured":"Wang H, Guo M, Wei H, Chen Y (2023) Targeting p53 pathways: mechanisms, structures and advances in therapy, Sig Transduct Target Ther, vol. 8, no. 1, pp. 1\u201335, Mar. https:\/\/doi.org\/10.1038\/s41392-023-01347-1","DOI":"10.1038\/s41392-023-01347-1"},{"key":"12666_CR10","doi-asserted-by":"publisher","unstructured":"Levine AJ (Aug. 2020) p53: 800 million years of evolution and 40 years of discovery. Nat Rev Cancer 20(8):471\u2013480. https:\/\/doi.org\/10.1038\/s41568-020-0262-1","DOI":"10.1038\/s41568-020-0262-1"},{"key":"12666_CR11","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Fontela C, Mandinova A, Aaronson SA, Lee SW (2016) Emerging roles of p53 and other tumour-suppressor genes in immune regulation, Nat Rev Immunol, vol. 16, no. 12, pp. 741\u2013750, Dec. https:\/\/doi.org\/10.1038\/nri.2016.99","DOI":"10.1038\/nri.2016.99"},{"key":"12666_CR12","doi-asserted-by":"publisher","unstructured":"Mijit M, Caracciolo V, Melillo A, Amicarelli F, Giordano A (2020) Role of p53 in the Regulation of Cellular Senescence, Biomolecules, vol. 10, no. 3, p. 420, Mar. https:\/\/doi.org\/10.3390\/biom10030420","DOI":"10.3390\/biom10030420"},{"key":"12666_CR13","doi-asserted-by":"publisher","unstructured":"Tam HH et al (Jul. 2023) Potential enhancement of post-stroke angiogenic response by targeting the oligomeric aggregation of p53 protein. Front Cell Neurosci 17:1193362. https:\/\/doi.org\/10.3389\/fncel.2023.1193362","DOI":"10.3389\/fncel.2023.1193362"},{"key":"12666_CR14","doi-asserted-by":"publisher","unstructured":"Bao Y-N et al (May 2024) Targeting tumor suppressor p53 for organ fibrosis therapy. Cell Death Dis 15(5):336. https:\/\/doi.org\/10.1038\/s41419-024-06702-w","DOI":"10.1038\/s41419-024-06702-w"},{"key":"12666_CR15","doi-asserted-by":"publisher","unstructured":"Aubrey BJ, Kelly GL, Janic A, Herold MJ, Strasser A (Jan. 2018) How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression? Cell Death Differ 25(1):104\u2013113. https:\/\/doi.org\/10.1038\/cdd.2017.169","DOI":"10.1038\/cdd.2017.169"},{"key":"12666_CR16","doi-asserted-by":"publisher","unstructured":"Dhokia V, Moss JAY, Macip S, Fox JL (Jan. 2022) At the Crossroads of Life and Death: The Proteins That Influence Cell Fate Decisions. Cancers 14 11, Art. 11. https:\/\/doi.org\/10.3390\/cancers14112745","DOI":"10.3390\/cancers14112745"},{"key":"12666_CR17","doi-asserted-by":"publisher","unstructured":"Huang W, Hickson LJ, Eirin A, Kirkland JL, Lerman LO (2022) Cellular senescence: the good, the bad and the unknown, Nat Rev Nephrol, vol. 18, no. 10, pp. 611\u2013627, Oct. https:\/\/doi.org\/10.1038\/s41581-022-00601-z","DOI":"10.1038\/s41581-022-00601-z"},{"key":"12666_CR18","doi-asserted-by":"publisher","unstructured":"Liu Y, Gu W (May 2022) p53 in ferroptosis regulation: the new weapon for the old guardian. Cell Death Differ 29(5):895\u2013910. https:\/\/doi.org\/10.1038\/s41418-022-00943-y","DOI":"10.1038\/s41418-022-00943-y"},{"key":"12666_CR19","doi-asserted-by":"publisher","unstructured":"Zeng L et al (Jul. 2024) Advances in research on immunocyte iron metabolism, ferroptosis, and their regulatory roles in autoimmune and autoinflammatory diseases. Cell Death Dis 15:481. https:\/\/doi.org\/10.1038\/s41419-024-06807-2","DOI":"10.1038\/s41419-024-06807-2"},{"key":"12666_CR20","doi-asserted-by":"publisher","unstructured":"Efe G, Rustgi AK, Prives C (Jul. 2024) p53 at the crossroads of tumor immunity. Nat Cancer 5(7):983\u2013995. https:\/\/doi.org\/10.1038\/s43018-024-00796-z","DOI":"10.1038\/s43018-024-00796-z"},{"key":"12666_CR21","doi-asserted-by":"publisher","unstructured":"Watanabe M, Moon KD, Vacchio MS, Hathcock KS, Hodes RJ (May 2014) Downmodulation of Tumor Suppressor p53 by T Cell Receptor Signaling Is Critical for Antigen-Specific CD4\u2009+\u2009T Cell Responses. Immunity 40(5):681\u2013691. https:\/\/doi.org\/10.1016\/j.immuni.2014.04.006","DOI":"10.1016\/j.immuni.2014.04.006"},{"key":"12666_CR22","doi-asserted-by":"publisher","unstructured":"Cui X, Li C-G, Gao H, Cheng M, Jiang F (Dec. 2023) Boosting regulatory T cell-dependent immune tolerance by activation of p53. Int Immunopharmacol 125:111167. https:\/\/doi.org\/10.1016\/j.intimp.2023.111167","DOI":"10.1016\/j.intimp.2023.111167"},{"key":"12666_CR23","doi-asserted-by":"publisher","unstructured":"Gudkov AV, Gurova KV, Komarova EA (2011) Inflammation and p53, Genes Cancer, vol. 2, no. 4, pp. 503\u2013516, Apr. https:\/\/doi.org\/10.1177\/1947601911409747","DOI":"10.1177\/1947601911409747"},{"key":"12666_CR24","doi-asserted-by":"publisher","unstructured":"Carr\u00e0 G, Lingua MF, Maffeo B, Taulli R, Morotti A (2020) P53 vs NF-\u03baB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa, Cell Mol Life Sci, vol. 77, no. 22, pp. 4449\u20134458, Nov. https:\/\/doi.org\/10.1007\/s00018-020-03524-9","DOI":"10.1007\/s00018-020-03524-9"},{"key":"12666_CR25","doi-asserted-by":"publisher","unstructured":"Jang H et al (Jan. 2020) The Tumor Suppressor, p53, Negatively Regulates Non-Canonical NF-\u03baB Signaling through miRNA-Induced Silencing of NF-\u03baB\u2013Inducing Kinase. Mol Cells 43(1):23\u201333. https:\/\/doi.org\/10.14348\/molcells.2019.0239","DOI":"10.14348\/molcells.2019.0239"},{"key":"12666_CR26","doi-asserted-by":"publisher","first-page":"1148389","DOI":"10.3389\/fmolb.2023.1148389","volume":"10","author":"L Carlsen","year":"2023","unstructured":"Carlsen L et al (2023) The role of p53 in anti-tumor immunity and response to immunotherapy. Front Mol Biosci 10:1148389. https:\/\/doi.org\/10.3389\/fmolb.2023.1148389","journal-title":"Front Mol Biosci"},{"key":"12666_CR27","doi-asserted-by":"publisher","first-page":"762651","DOI":"10.3389\/fcell.2021.762651","volume":"9","author":"D Shi","year":"2021","unstructured":"Shi D, Jiang P (2021) A Different Facet of p53 Function: Regulation of Immunity and Inflammation During Tumor Development. Front Cell Dev Biol 9:762651. https:\/\/doi.org\/10.3389\/fcell.2021.762651","journal-title":"Front Cell Dev Biol"},{"key":"12666_CR28","doi-asserted-by":"publisher","unstructured":"Liu Z-L, Chen H-H, Zheng L-L, Sun L-P, Shi L (May 2023) Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Sig Transduct Target Ther 8(1):1\u201339. https:\/\/doi.org\/10.1038\/s41392-023-01460-1","DOI":"10.1038\/s41392-023-01460-1"},{"key":"12666_CR29","doi-asserted-by":"publisher","unstructured":"Hern\u00e1ndez Borrero LJ, El-Deiry WS (2021) Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol. 1876, no. 1, p. 188556, Aug. https:\/\/doi.org\/10.1016\/j.bbcan.2021.188556","DOI":"10.1016\/j.bbcan.2021.188556"},{"key":"12666_CR30","doi-asserted-by":"publisher","unstructured":"Matteo AD, Bathon JM, Emery P (Nov. 2023) Rheumatoid arthritis. Lancet 402(10416):2019\u20132033. https:\/\/doi.org\/10.1016\/S0140-6736(23)01525-8","DOI":"10.1016\/S0140-6736(23)01525-8"},{"key":"12666_CR31","doi-asserted-by":"publisher","unstructured":"Abuetabh Y et al (Oct. 2022) DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. Exp Mol Med 54(10):1658\u20131669. https:\/\/doi.org\/10.1038\/s12276-022-00863-4","DOI":"10.1038\/s12276-022-00863-4"},{"key":"12666_CR32","unstructured":"Firestein GS, Nguyen K, Aupperle KR, Yeo M, Boyle DL, Zvaifler NJ (1996) Apoptosis in Rheumatoid Arthritis, 149, 6"},{"key":"12666_CR33","doi-asserted-by":"publisher","unstructured":"Zhang KX et al (Oct. 2020) Drug-resistance in rheumatoid arthritis: the role of p53 gene mutations, ABC family transporters and personal factors. Curr Opin Pharmacol 54:59\u201371. https:\/\/doi.org\/10.1016\/j.coph.2020.08.002","DOI":"10.1016\/j.coph.2020.08.002"},{"key":"12666_CR34","doi-asserted-by":"publisher","unstructured":"Ebrahimian H et al (Jul. 2023) Altered expression of apoptosis-related genes in rheumatoid arthritis peripheral blood mononuclear cell and related miRNA regulation. Immunity Inflam Disease 11(7):e914. https:\/\/doi.org\/10.1002\/iid3.914","DOI":"10.1002\/iid3.914"},{"key":"12666_CR35","doi-asserted-by":"publisher","unstructured":"Jung SM, Park K-S, Kim K-J (2021) Deep phenotyping of synovial molecular signatures by integrative systems analysis in rheumatoid arthritis, Rheumatology, vol. 60, no. 7, pp. 3420\u20133431, Jul. https:\/\/doi.org\/10.1093\/rheumatology\/keaa751","DOI":"10.1093\/rheumatology\/keaa751"},{"key":"12666_CR36","doi-asserted-by":"publisher","unstructured":"Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS (2002) Regional analysis of p53 mutations in rheumatoid arthritis synovium, Proc Natl Acad Sci U S A, vol. 99, no. 15, pp. 10025\u201310030, Jul. https:\/\/doi.org\/10.1073\/pnas.152333199","DOI":"10.1073\/pnas.152333199"},{"key":"12666_CR37","doi-asserted-by":"publisher","unstructured":"Igarashi H, Hashimoto J, Tomita T, Yoshikawa H, Ishihara K (2010) TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis, Clin Exp Immunol, vol. 161, no. 1, pp. 71\u201380, Jul. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04163.x","DOI":"10.1111\/j.1365-2249.2010.04163.x"},{"key":"12666_CR38","doi-asserted-by":"publisher","unstructured":"Tak PP et al (May 1999) P53 overexpression in synovial tissue from patients with early and longstanding rheumatoid arthritis compared with patients with reactive arthritis and osteoarthritis. Arthritis Rheumatism 42(5):948\u2013953. https:\/\/doi.org\/10.1002\/1529-0131(199905)42:5%3C948::AID-ANR13%3E3.0.CO;2-L","DOI":"10.1002\/1529-0131(199905)42:5%3C948::AID-ANR13%3E3.0.CO;2-L"},{"key":"12666_CR39","doi-asserted-by":"publisher","unstructured":"Qiu C et al (Mar. 2023) The potential development of drug resistance in rheumatoid arthritis patients identified with p53 mutations. Genes Dis 10(6):2252\u20132255. https:\/\/doi.org\/10.1016\/j.gendis.2023.02.007","DOI":"10.1016\/j.gendis.2023.02.007"},{"key":"12666_CR40","doi-asserted-by":"publisher","unstructured":"Sun Y et al (2000) Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13), Journal of Biological Chemistry, vol. 275, no. 15, pp. 11327\u201311332, Apr. https:\/\/doi.org\/10.1074\/jbc.275.15.11327","DOI":"10.1074\/jbc.275.15.11327"},{"key":"12666_CR41","doi-asserted-by":"publisher","unstructured":"Zeng Y et al (2023) Mutant p53R211* ameliorates inflammatory arthritis in AIA rats via inhibition of TBK1-IRF3 innate immune response, Inflamm. Res., vol. 72, no. 12, pp. 2199\u20132219, Dec. https:\/\/doi.org\/10.1007\/s00011-023-01809-w","DOI":"10.1007\/s00011-023-01809-w"},{"key":"12666_CR42","doi-asserted-by":"publisher","unstructured":"Ding Q et al (Feb. 2023) Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Sig Transduct Target Ther 8(1):1\u201324. https:\/\/doi.org\/10.1038\/s41392-023-01331-9","DOI":"10.1038\/s41392-023-01331-9"},{"key":"12666_CR43","doi-asserted-by":"publisher","unstructured":"Pap T, Aupperle KR, Gay S, Firestein GS, Gay RE (Mar. 2001) Invasiveness of synovial fibroblasts is regulated by p53 in the SCID mouse in vivo model of cartilage invasion. Arthritis Rheumatism 44(3):676\u2013681. https:\/\/doi.org\/10.1002\/1529-0131(200103)44:3%3C676::AID-ANR117%3E3.0.CO;2-6","DOI":"10.1002\/1529-0131(200103)44:3%3C676::AID-ANR117%3E3.0.CO;2-6"},{"key":"12666_CR44","doi-asserted-by":"publisher","unstructured":"Jasim SA et al (Mar. 2022) Shining the light on clinical application of mesenchymal stem cell therapy in autoimmune diseases. Stem Cell Research Therapy 13(1):101. https:\/\/doi.org\/10.1186\/s13287-022-02782-7","DOI":"10.1186\/s13287-022-02782-7"},{"key":"12666_CR45","doi-asserted-by":"publisher","unstructured":"Wu H et al (2021) miR-34a in extracellular vesicles from bone marrow mesenchymal stem cells reduces rheumatoid arthritis inflammation via the cyclin I\/ATM\/ATR\/p53 axis, J Cellular Molecular Medi, vol. 25, no. 4, pp. 1896\u20131910, Feb. https:\/\/doi.org\/10.1111\/jcmm.15857","DOI":"10.1111\/jcmm.15857"},{"key":"12666_CR46","doi-asserted-by":"publisher","unstructured":"Hou H, Xing W, Li W (Dec. 2016) Brahma-related gene 1 induces apoptosis in a p53-dependent manner in human rheumatoid fibroblast-like synoviocyte MH7A. Medicine 95(51):e5241. https:\/\/doi.org\/10.1097\/MD.0000000000005241","DOI":"10.1097\/MD.0000000000005241"},{"key":"12666_CR47","doi-asserted-by":"publisher","unstructured":"Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C (1990) Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis, Ann Rheum Dis, vol. 49, no. 9, pp. 665\u2013667, Sep. https:\/\/doi.org\/10.1136\/ard.49.9.665","DOI":"10.1136\/ard.49.9.665"},{"key":"12666_CR48","unstructured":"Nakazawa M, Aratani S TNFa induces acetylation of p53 but attenuates its transcriptional activation in rheumatoid synoviocytes"},{"key":"12666_CR49","doi-asserted-by":"publisher","unstructured":"Leech M et al (2003) Regulation of p53 by macrophage migration inhibitory factor in inflammatory arthritis, Arthritis & Rheumatism, vol. 48, no. 7, pp. 1881\u20131889, Jul. https:\/\/doi.org\/10.1002\/art.11165","DOI":"10.1002\/art.11165"},{"key":"12666_CR50","doi-asserted-by":"publisher","unstructured":"Zhao C et al (Apr. 2024) Sulfasalazine promotes ferroptosis through AKT-ERK1\/2 and P53-SLC7A11 in rheumatoid arthritis. Inflammopharmacol 32(2):1277\u20131294. https:\/\/doi.org\/10.1007\/s10787-024-01439-6","DOI":"10.1007\/s10787-024-01439-6"},{"key":"12666_CR51","doi-asserted-by":"publisher","unstructured":"Park J-S et al (2013) p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell\/Treg cell balance in mice, Arthritis Rheum, vol. 65, no. 4, pp. 949\u2013959, Apr. https:\/\/doi.org\/10.1002\/art.37841","DOI":"10.1002\/art.37841"},{"key":"12666_CR52","unstructured":"Tang B-X et al (2011) p53 in fibroblast-like synoviocytes can regulate T helper cell functions in patients with active rheumatoid arthritis, Chin Med J (Engl), vol. 124, no. 3, pp. 364\u2013368, Feb"},{"key":"12666_CR53","doi-asserted-by":"publisher","unstructured":"Leech M et al (2008) The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response, Clinical and Experimental Immunology, vol. 152, no. 2, pp. 345\u2013353, Apr. https:\/\/doi.org\/10.1111\/j.1365-2249.2008.03629.x","DOI":"10.1111\/j.1365-2249.2008.03629.x"},{"key":"12666_CR54","doi-asserted-by":"publisher","unstructured":"Yamanishi Y et al (Jan. 2002) Regulation of Joint Destruction and Inflammation by p53 in Collagen-Induced Arthritis. Am J Pathol 160(1):123\u2013130. https:\/\/doi.org\/10.1016\/S0002-9440(10)64356-8","DOI":"10.1016\/S0002-9440(10)64356-8"},{"key":"12666_CR55","doi-asserted-by":"publisher","unstructured":"\u0160imelyte E, Rosengren S, Boyle DL, Corr M, Green DR, Firestein GS (2005) Regulation of arthritis by p53: Critical role of adaptive immunity, Arthritis & Rheumatism, vol. 52, no. 6, pp. 1876\u20131884, Jun. https:\/\/doi.org\/10.1002\/art.21099","DOI":"10.1002\/art.21099"},{"key":"12666_CR56","doi-asserted-by":"publisher","unstructured":"Zhang T et al (Dec. 2016) p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis. Arthritis Res Ther 18(1):271. https:\/\/doi.org\/10.1186\/s13075-016-1161-4","DOI":"10.1186\/s13075-016-1161-4"},{"key":"12666_CR57","doi-asserted-by":"publisher","unstructured":"Zhang L, Luo J, Wen H, Zhang T, Zuo X, Li X (Jan. 2016) MDM2 promotes rheumatoid arthritis via activation of MAPK and NF-\u03baB. Int Immunopharmacol 30:69\u201373. https:\/\/doi.org\/10.1016\/j.intimp.2015.11.030","DOI":"10.1016\/j.intimp.2015.11.030"},{"key":"12666_CR58","doi-asserted-by":"publisher","unstructured":"Spurlock CF, Tossberg JT, Matlock BK, Olsen NJ, Aune TM (2014) Methotrexate inhibits NF-\u03baB activity via long intergenic (noncoding) RNA-p21 induction, Arthritis Rheumatol, vol. 66, no. 11, pp. 2947\u20132957, Nov. https:\/\/doi.org\/10.1002\/art.38805","DOI":"10.1002\/art.38805"},{"key":"12666_CR59","doi-asserted-by":"publisher","unstructured":"Lin J et al (Jan. 2014) A novel p53\/microRNA-22\/Cyr61 axis in synovial cells regulates inflammation in rheumatoid arthritis. Arthritis Rheumatol 66(1):49\u201359. https:\/\/doi.org\/10.1002\/art.38142","DOI":"10.1002\/art.38142"},{"key":"12666_CR60","doi-asserted-by":"publisher","unstructured":"Lin J et al (2012) Cyr61 Induces IL-6 Production by Fibroblast-like Synoviocytes Promoting Th17 Differentiation in Rheumatoid Arthritis, The Journal of Immunology, vol. 188, no. 11, pp. 5776\u20135784, Jun. https:\/\/doi.org\/10.4049\/jimmunol.1103201","DOI":"10.4049\/jimmunol.1103201"},{"key":"12666_CR61","doi-asserted-by":"publisher","unstructured":"Wolf ER, Mabry AR, Damania B, Mayo LD (2020) Mdm2-mediated neddylation of pVHL blocks the induction of antiangiogenic factors, Oncogene, vol. 39, no. 29, pp. 5228\u20135239, Jul. https:\/\/doi.org\/10.1038\/s41388-020-1359-4","DOI":"10.1038\/s41388-020-1359-4"},{"key":"12666_CR62","doi-asserted-by":"publisher","first-page":"793855","DOI":"10.3389\/fimmu.2022.793855","volume":"13","author":"Y Chen","year":"2022","unstructured":"Chen Y et al (2022) RA Fibroblast-Like Synoviocytes Derived Extracellular Vesicles Promote Angiogenesis by miRNA-1972 Targeting p53\/mTOR Signaling in Vascular Endotheliocyte. Front Immunol 13:793855. https:\/\/doi.org\/10.3389\/fimmu.2022.793855","journal-title":"Front Immunol"},{"key":"12666_CR63","doi-asserted-by":"publisher","unstructured":"Tsokos GC (2024) The immunology of systemic lupus erythematosus, Nat Immunol, vol. 25, no. 8, pp. 1332\u20131343, Aug. https:\/\/doi.org\/10.1038\/s41590-024-01898-7","DOI":"10.1038\/s41590-024-01898-7"},{"issue":"4","key":"12666_CR64","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000074428","volume":"24","author":"C Miret","year":"2003","unstructured":"Miret C et al (2003) Relationship of p53 with other Oncogenes, Cytokines and Systemic Lupus Erythematosus Activity. Tumor Biol 24(4):185\u2013188. https:\/\/doi.org\/10.1159\/000074428","journal-title":"Tumor Biol"},{"key":"12666_CR65","doi-asserted-by":"publisher","unstructured":"El-Sayed ZA, Farag DH, Eissa S (Jun. 2003) Tumor suppressor protein p53 and anti-p53 autoantibodies in pediatric rheumatological diseases. Pediatr Allergy Immunol 14(3):229\u2013233. https:\/\/doi.org\/10.1034\/j.1399-3038.2003.00033.x","DOI":"10.1034\/j.1399-3038.2003.00033.x"},{"key":"12666_CR66","doi-asserted-by":"publisher","unstructured":"Chauhan R, Handa R, Das TP, Pati U (Jun. 2004) Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin Exp Immunol 136(3):574\u2013584. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02463.x","DOI":"10.1111\/j.1365-2249.2004.02463.x"},{"key":"12666_CR67","doi-asserted-by":"publisher","unstructured":"Alvarado-de la C, Barrera J, Alcocer-Varela Y, Richaud-Patin D, Alarc\u00f3n-Segovia, Llorente L (1998) Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients, Scand J Immunol, vol. 48, no. 5, pp. 551\u2013556, Nov. https:\/\/doi.org\/10.1046\/j.1365-3083.1998.00427.x","DOI":"10.1046\/j.1365-3083.1998.00427.x"},{"key":"12666_CR68","doi-asserted-by":"publisher","unstructured":"Xie S, Chen T, Li L, Tan C, Jiang P (Mar. 2026) Loss of p53 exacerbates autoimmunity by reprogramming propionyl-CoA metabolism and histone modifications in Treg cells. Cell Rep 45(3). https:\/\/doi.org\/10.1016\/j.celrep.2026.117084","DOI":"10.1016\/j.celrep.2026.117084"},{"key":"12666_CR69","doi-asserted-by":"publisher","unstructured":"Herkel J et al (2001) Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies, J Autoimmun, vol. 17, no. 1, pp. 63\u201369, Aug. https:\/\/doi.org\/10.1006\/jaut.2001.0518","DOI":"10.1006\/jaut.2001.0518"},{"key":"12666_CR70","doi-asserted-by":"publisher","unstructured":"Herkel J et al (Apr. 2000) Systemic lupus erythematosus in mice, spontaneous and induced, is associated with autoimmunity to the C-terminal domain of p53 that recognizes damaged DNA. Eur J Immunol 30(4):977\u2013984. https:\/\/doi.org\/10.1002\/(SICI)1521-4141(200004)30:4%3C977::AID-IMMU977%3E3.0.CO;2-A","DOI":"10.1002\/(SICI)1521-4141(200004)30:4%3C977::AID-IMMU977%3E3.0.CO;2-A"},{"key":"12666_CR71","doi-asserted-by":"publisher","unstructured":"Wu Y et al (Oct. 2024) CX-5461 ameliorates disease in lupus-prone mice by triggering B-cell ferroptosis via p53-SLC7A11-ALOX12 pathway. Free Radic Biol Med 223:325\u2013340. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2024.08.003","DOI":"10.1016\/j.freeradbiomed.2024.08.003"},{"key":"12666_CR72","doi-asserted-by":"publisher","unstructured":"Dao LTM, Vu TT, Nguyen QT, Hoang VT, Nguyen TL (2024) Current cell therapies for systemic lupus erythematosus, Stem Cells Transl Med, vol. 13, no. 9, pp. 859\u2013872, Jun. https:\/\/doi.org\/10.1093\/stcltm\/szae044","DOI":"10.1093\/stcltm\/szae044"},{"key":"12666_CR73","doi-asserted-by":"publisher","unstructured":"Gao L et al (2017) Human SLE bone marrow mesenchymal stem cells (BMSCs) have a senescence-associated secretory phenotype (SASP) mediated by a MAVS-IFN\u03b2 feedback loop, Arthritis & rheumatology (Hoboken, N.J.), vol. 69, no. 8, p. 1623, Jul. https:\/\/doi.org\/10.1002\/art.40142","DOI":"10.1002\/art.40142"},{"key":"12666_CR74","doi-asserted-by":"publisher","unstructured":"Gu Z et al (Feb. 2014) Wnt\/\u03b2-catenin signaling mediates the senescence of bone marrow-mesenchymal stem cells from systemic lupus erythematosus patients through the p53\/p21 pathway. Mol Cell Biochem 387:1\u20132. https:\/\/doi.org\/10.1007\/s11010-013-1866-5","DOI":"10.1007\/s11010-013-1866-5"},{"key":"12666_CR75","doi-asserted-by":"publisher","unstructured":"Teng Z, Lin X, Luan C, Sun Y, Li X (2021) The high expression of miR-564 in patients with systemic lupus erythematosus promotes differentiation and maturation of DC cells by negatively regulating TP53 expression in vitro, Lupus, vol. 30, no. 9, pp. 1469\u20131480, Aug. https:\/\/doi.org\/10.1177\/09612033211020367","DOI":"10.1177\/09612033211020367"},{"key":"12666_CR76","doi-asserted-by":"publisher","unstructured":"Salvador JM et al (2002) Mice Lacking the p53-Effector Gene Gadd45a Develop a Lupus-Like Syndrome, Immunity, vol. 16, no. 4, pp. 499\u2013508, Apr. https:\/\/doi.org\/10.1016\/S1074-7613(02)00302-3","DOI":"10.1016\/S1074-7613(02)00302-3"},{"key":"12666_CR77","doi-asserted-by":"publisher","unstructured":"Zhang Q et al (2022) Deficiency of p53 Causes the Inadequate Expression of miR-1246 in B Cells of Systemic Lupus Erythematosus, The Journal of Immunology, vol. 209, no. 8, pp. 1492\u20131498, Oct. https:\/\/doi.org\/10.4049\/jimmunol.2200307","DOI":"10.4049\/jimmunol.2200307"},{"key":"12666_CR78","doi-asserted-by":"publisher","unstructured":"Luo S et al (Dec. 2015) The role of microRNA-1246 in the regulation of B cell activation and the pathogenesis of systemic lupus erythematosus. Clin Epigenet 7(1):24. https:\/\/doi.org\/10.1186\/s13148-015-0063-7","DOI":"10.1186\/s13148-015-0063-7"},{"key":"12666_CR79","doi-asserted-by":"publisher","unstructured":"Kuan AP, Cohen PL (May 2005) p53 is required for spontaneous autoantibody production in B6\/lpr lupus mice. Eur J Immunol 35(5):1653\u20131660. https:\/\/doi.org\/10.1002\/eji.200525982","DOI":"10.1002\/eji.200525982"},{"key":"12666_CR80","doi-asserted-by":"publisher","unstructured":"Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T (2023) State-of-the-art evidence in the treatment of systemic sclerosis, Nat Rev Rheumatol, vol. 19, no. 4, pp. 212\u2013226, Apr. https:\/\/doi.org\/10.1038\/s41584-023-00909-5","DOI":"10.1038\/s41584-023-00909-5"},{"key":"12666_CR81","unstructured":"Hara T et al (2008) Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis, J Rheumatol, vol. 35, no. 3, pp. 451\u2013457, Mar"},{"key":"12666_CR82","doi-asserted-by":"publisher","unstructured":"Yamamoto T, Nishioka K (May 2005) Increased expression of p53 and p21 (Waf1\/Cip1) in the lesional skin of bleomycin-induced scleroderma. Arch Dermatol Res 296(11):509\u2013513. https:\/\/doi.org\/10.1007\/s00403-005-0550-3","DOI":"10.1007\/s00403-005-0550-3"},{"key":"12666_CR83","doi-asserted-by":"publisher","unstructured":"Sfikakis PP, Gorgoulis VG, Kapsogeorgou EK, Tsoli E, Manoussakis MN (2002) Absence of p53 gene mutations in skin fibroblasts derived from patients with systemic sclerosis, Eur J Clin Investigation, vol. 32, no. 2, pp. 139\u2013140, Feb. https:\/\/doi.org\/10.1046\/j.1365-2362.2002.00943.x","DOI":"10.1046\/j.1365-2362.2002.00943.x"},{"key":"12666_CR84","doi-asserted-by":"publisher","unstructured":"Mahmoudi MB et al (2018) Expressions of p53 and PUMA in fibroblasts of systemic sclerosis patients are normal at transcription level, J of Cosmetic Dermatology, vol. 17, no. 3, pp. 549\u2013554, Jun. https:\/\/doi.org\/10.1111\/jocd.12420","DOI":"10.1111\/jocd.12420"},{"key":"12666_CR85","doi-asserted-by":"publisher","unstructured":"Chauhan R, Handa R, Das TP, Pati U (May 2004) Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin Exp Immunol 136(3):574\u2013584. https:\/\/doi.org\/10.1111\/j.1365-2249.2004.02463.x","DOI":"10.1111\/j.1365-2249.2004.02463.x"},{"key":"12666_CR86","doi-asserted-by":"publisher","unstructured":"Wang W et al (Apr. 2026) p53: from understanding its structure to advances in therapeutic targeting. Sig Transduct Target Ther 11(1):121. https:\/\/doi.org\/10.1038\/s41392-025-02549-5","DOI":"10.1038\/s41392-025-02549-5"},{"key":"12666_CR87","doi-asserted-by":"publisher","unstructured":"Peuget S, Zhou X, Selivanova G (2024) Translating p53-based therapies for cancer into the clinic, Nat Rev Cancer, vol. 24, no. 3, pp. 192\u2013215, Mar. https:\/\/doi.org\/10.1038\/s41568-023-00658-3","DOI":"10.1038\/s41568-023-00658-3"},{"key":"12666_CR88","doi-asserted-by":"publisher","unstructured":"Allam R, Sayyed SG, Kulkarni OP, Lichtnekert J, Anders H-J (2011) Mdm2 Promotes Systemic Lupus Erythematosus and Lupus Nephritis, Journal of the American Society of Nephrology, vol. 22, no. 11, pp. 2016\u20132027, Nov. https:\/\/doi.org\/10.1681\/ASN.2011010045","DOI":"10.1681\/ASN.2011010045"},{"key":"12666_CR89","doi-asserted-by":"publisher","unstructured":"Adib M et al (Feb. 2023) Anti-inflammatory effects of PRIMA-1MET (mutant p53 reactivator) induced by inhibition of nuclear factor-\u03baB on rheumatoid arthritis fibroblast-like synoviocytes. Inflammopharmacol 31(1):385\u2013394. https:\/\/doi.org\/10.1007\/s10787-022-01094-9","DOI":"10.1007\/s10787-022-01094-9"},{"key":"12666_CR90","doi-asserted-by":"publisher","unstructured":"Savostyanova TA, Lopatnikova JA, Sennikov SVV (2026) The guardian of the genome meets immunotherapy: p53-based strategies, Front. Immunol., vol. 17, Mar. https:\/\/doi.org\/10.3389\/fimmu.2026.1762679","DOI":"10.3389\/fimmu.2026.1762679"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12666-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12666-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:16:56Z","timestamp":1787923016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12666-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12666"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12666-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1483"}}